EMA Approves Factor VIII Deficiency Clotting Drug EMA Approves Factor VIII Deficiency Clotting Drug
European Union marketing authorization recommended for Altuvoct for hemophilia A caused by factor VIII deficiency.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 26, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Clue to Aspirin, Colon Cancer Link; New Lutathera Approval; AI & Electronic Records
(MedPage Today) -- Possibly uncovering a clue to a longstanding mystery, Italian researchers found that aspirin may help prevent colorectal cancer by pointing the immune system toward cancer cells. (Cancer)
The FDA expanded indications for lutetium... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 26, 2024 Category: Hematology Source Type: news
Conference MDAngle: AUA 2024 Metastatic Prostate Cancer Conference MDAngle: AUA 2024 Metastatic Prostate Cancer
Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2024 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
AUA 2024: Awaiting New Data in Metastatic Prostate Cancer AUA 2024: Awaiting New Data in Metastatic Prostate Cancer
Dr Kelvin Moses previews some of the exciting trials and guideline updates being presented at AUA 2024.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2024 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Quadruplet Shows 'Excellent Activity' in Myeloma Patients Who Defer HSCT
(MedPage Today) -- Adding the CD38 monoclonal antibody isatuximab (Sarclisa) to a backbone of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) induced deep and durable responses in a multiple myeloma study of untreated transplant... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 26, 2024 Category: Hematology Source Type: news
Europe Recommends Three Cancer Drugs Europe Recommends Three Cancer Drugs
The European Medicines Agency has recommended Fruzaqla, Truqap, and Eribulin Baxter for use in the treatment of specific colorectal and breast cancers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 26, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Guidelines Don ’t Eliminate Variations in Chemotherapy Uptake Guidelines Don ’t Eliminate Variations in Chemotherapy Uptake
Prof David Kerr discusses the disconnect between national and international guidelines and variations in chemotherapy uptake.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2024 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Definitive Therapy Ups Survival in Brain-Only Mets NSCLC Definitive Therapy Ups Survival in Brain-Only Mets NSCLC
Definitive treatment to the primary site improves overall and cancer-specific survival among patients with brain-only NSCLC metastases, a recent retrospective study shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 26, 2024 Category: Consumer Health News Tags: Hematology-Oncology Clinical Summary Source Type: news
Pancreatic Fat Is the Main Driver for Pancreatic Diseases Pancreatic Fat Is the Main Driver for Pancreatic Diseases
The diffused presence of fat within the pancreas was the single most important driver for diseases of both the exocrine pancreas and endocrine pancreas, a recent study reported.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 26, 2024 Category: Cancer & Oncology Tags: Gastroenterology Clinical Summary Source Type: news
Mapping a Positive Way Forward for Bowel Cancer Screening Mapping a Positive Way Forward for Bowel Cancer Screening
Prof David Kerr discusses insights on improving screening for colorectal cancer.Medscape Oncology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 25, 2024 Category: Pathology Tags: Hematology-Oncology Commentary Source Type: news
Don't Miss the Dx: Woman Has Unintended Weight Loss, Fatigue Don't Miss the Dx: Woman Has Unintended Weight Loss, Fatigue
Are you familiar with the presentation, workup, treatment, and monitoring of CML? Dr Adam Braun provides a brief guide.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 25, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
ESMO Recap: Adjuvant Vs. Neoadjuvant Therapy in Melanoma ESMO Recap: Adjuvant Vs. Neoadjuvant Therapy in Melanoma
Dr Jeffrey Weber discusses adjuvant and neoadjuvant therapy in melanoma.Medscape Oncology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 25, 2024 Category: Radiology Tags: Hematology-Oncology Commentary Source Type: news
How to Improve Radiotherapy Decisions in Endometrial Cancer How to Improve Radiotherapy Decisions in Endometrial Cancer
Radiotherapy decisions should be made using refined genomic guidance, as recommended by 2021 updated international guidelines, to better identify patients with molecularly aggressive disease.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 25, 2024 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Timing Is Everything: CAR T for Follicular Lymphoma Timing Is Everything: CAR T for Follicular Lymphoma
CAR T-cell therapy is the best option for patients with relapsed/refractory follicular lymphoma, even though it comes with serious side effects.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 25, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
High Deep-Remission Rate With Triple Regimen for Relapsed/Refractory CLL
(MedPage Today) -- Time-limited treatment with a three-drug combination for relapsed/refractory chronic lymphocytic leukemia (CLL) produced long-term undetectable residual disease in more than 90% of patients, updated results from a prospective... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 25, 2024 Category: Hematology Source Type: news
